-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

Benzinga·10/22/2026 13:42:03
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.